Follow The Filings

ARXS Arxis

Arxis earnings company data as of 4:47 AM ET 10/19

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS 0.24 — —
Rev — — —

Insider trades

Open-market buys and sales by ARXS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ARXS insider trades
  • $5.6M bought by 7 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Ryan Anthony Jankowski Chief Accounting Officer
    Buy
    $125K 4,464 shares at $28.00 +9.5% to stake
    Traded Apr 17 Filed Apr 20
  2. Azad Sid Badakhsh See Remarks
    Buy
    $1M 36,000 shares at $28.00 +9.8% to stake
    Traded Apr 17 Filed Apr 20
  3. Ross Bradley Sealfon See Remarks
    Buy
    $350K 12,500 shares at $28.00 +1.1% to stake
    Traded Apr 17 Filed Apr 20
  4. Stephen Duane Oetgen Director
    Buy
    $700K 25,000 shares at $28.00 +467% to stake
    Traded Apr 17 Filed Apr 20
  5. Patrick E Allen Director
    Buy
    $280K 10,000 shares at $28.00 +187% to stake
    Traded Apr 17 Filed Apr 20
  6. Kevin Scott Perhamus See Remarks
    Buy
    $1.5M 53,600 shares at $28.00 +1.5% to stake
    Traded Apr 17 Filed Apr 20
  7. Jason Aaron Roth See Remarks
    Buy
    $1.7M 60,000 shares at $28.00 +18% to stake
    Traded Apr 17 Filed Apr 20

Also filed in the last 12 months, not counted as buying or selling: 11 stock grants.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
424B3
S-1
SCHEDULE 13G —
8-K 2.01,3.02,9.01
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 1.01,8.01,9.01
10-Q
8-K 2.02,9.01
8-K 1.01,2.01,3.02,3.03,5.03,9.01
424B4
S-1/A
S-1/A
S-1

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.